SCHEMBL155707

SCHEMBL155707

CCc1ccc(OC(F)(F)F)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.58
ALDH1A1 P00352 1/20 0.53
SLC6A4 P31645 4/20 0.50
LMNA P02545 1/20 0.47
BCHE P06276 1/20 0.46
ACHE P22303 1/20 0.46
GRIN2B Q13224 1/20 0.46
NOS3 P29474 2/20 0.46
NOS1 P29475 2/20 0.46
NOS2 P35228 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
PDE2A O00408 1/20 0.46
SLC6A3 Q01959 3/20 0.45
EPHX2 P34913 1/20 0.45
NR1H4 Q96RI1 1/20 0.45
EPHX1 P07099 1/20 0.45
POLB P06746 1/20 0.45
KDM1A O60341 1/20 0.45
RCOR1 Q9UKL0 1/20 0.45
TP53 P04637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL25380785 0.98 TSHR (0.56) TSHRALDH1A1SLC6A4LMNABCHE
SCHEMBL9062148 0.94 TSHR (0.53) TSHRALDH1A1SLC6A4LMNABCHE
SCHEMBL9425434 0.94 TSHR (0.53) TSHRALDH1A1SLC6A4LMNABCHE
SCHEMBL2056132 0.94 TSHR (0.53) TSHRALDH1A1SLC6A4LMNABCHE
SCHEMBL2056279 0.94 TSHR (0.53) TSHRALDH1A1SLC6A4LMNABCHE
SCHEMBL9060664 0.88 TSHR (0.49) TSHRALDH1A1SLC6A4LMNABCHE
SCHEMBL14163891 0.88 RXRA (0.56) TSHRL3MBTL1
SCHEMBL8990621 0.88 TSHR (0.49) TSHRALDH1A1SLC6A4LMNASLC6A3
SCHEMBL8990856 0.88 TSHR (0.49) TSHRALDH1A1SLC6A4LMNASLC6A3
SCHEMBL9509352 0.88 ACACB (0.56) TSHRALDH1A1SLC6A4LMNABCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 659 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155751-A1 PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS AstraZeneca AB (SE) 2010-02-24 EP claimed
WO-2008136756-A1 PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS ASTRAZENECA AB (SE) 2008-11-13 WO claimed
US-6420398-B2 FOR TREATING AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS; 4-(3-(2-(ACETYLTHIO)ETHYL)-3-(2-CYCLOHEXYLETHYL)-UREIDOMETHYL)-1 -METHYLPYRIDINIUM IODIDE, FOR EXAMPLE; INHIBIT PRODUCTION OF TUMOR NECROSIS FACTOR ALPHA (TNF-A) SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US claimed
US-20010041725-A1 Novel urea derivatives having nitrogen aromatic heterocycle SANTEN PHARMACEUTICAL CO., LTD. (JP) 2001-11-15 US claimed
EP-1103543-A1 NOVEL UREA DERIVATIVES BEARING NITROGENOUS AROMATIC HETEROCYCLES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2001-05-30 EP claimed
US-20250129048-A1 MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER INC. (US) 2025-04-24 US disclosed
US-12043613-B2 Inhibitors of SARM1 DISARM THERAPEUTICS, INC. (US) 2024-07-23 US disclosed
WO-2024139260-A1 ALLICIN DERIVATIVES, PREPARATION METHOD THEREFOR, AND USES THEREOF 成都新朝阳作物科学股份有限公司 2024-07-04 WO disclosed
US-20240016775-A1 ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) 2024-01-18 US disclosed
US-11873288-B2 Inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-01-16 US disclosed
US-11858880-B2 Anti-fungals compounds targeting the synthesis of fungal sphingolipids THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2024-01-02 US disclosed
CN-116947720-A Allicin derivative and preparation method and application thereof 成都新朝阳作物科学股份有限公司 2023-10-27 CN disclosed
US-20010041725-A1 Novel urea derivatives having nitrogen aromatic heterocycle SANTEN PHARMACEUTICAL CO., LTD. (JP) 2001-11-15 US disclosed
EP-1103543-A1 NOVEL UREA DERIVATIVES BEARING NITROGENOUS AROMATIC HETEROCYCLES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2001-05-30 EP disclosed
EP-0394417-B1 SUPERTWIST LIQUID CRYSTAL DISPLAY MERCK PATENT GMBH (DE) 1994-10-26 EP disclosed
EP-0394419-B1 MATRIX LIQUID CRYSTAL DISPLAY MERCK PATENT GMBH (DE) 1994-09-21 EP disclosed
EP-0406468-A1 Nematic-liquid-crystal composition for active matrix application SHARP CORPORATION (JP) 1991-01-09 EP disclosed
EP-0394419-A1 MATRIX LIQUID CRYSTAL DISPLAY. MERCK PATENT GMBH (DE) 1990-10-31 EP disclosed
EP-0394417-A1 SUPERTWIST LIQUID CRYSTAL DISPLAY. MERCK PATENT GMBH (DE) 1990-10-31 EP disclosed
WO-1990004623-A1 MATRIX LIQUID CRYSTAL DISPLAY MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 1990-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240016775-A1 ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR PARP3, PARP1, PARP4 TSHR 4856/4885ALDH1A1 1311/4885SLC6A4 2710/4885
US-12043613-B2 Inhibitors of SARM1 SARM1, SMN1; SMN2, SARNP TSHR 3994/4885ALDH1A1 4157/4885SLC6A4 3410/4885
US-11873288-B2 Inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH) FAAH, FAAH2, EPHX2 TSHR 2275/4885ALDH1A1 261/4885SLC6A4 1808/4885
US-20010041725-A1 Novel urea derivatives having nitrogen aromatic heterocycle TNF, UACA, HRH4 TSHR 793/4885ALDH1A1 988/4885SLC6A4 3992/4885
US-11858880-B2 Anti-fungals compounds targeting the synthesis of fungal sphingolipids ERG28, UGCG, DPM1 TSHR 4805/4885ALDH1A1 4460/4885SLC6A4 3926/4885
US-20250129048-A1 MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF MC4R, MC3R, MC2R TSHR 26/4885ALDH1A1 3955/4885SLC6A4 459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.